Genetic Analysis receives important patent allowance in China
OSLO, NORWAY - 14 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has been awarded an important patent (CN107430644A) by the China National Intellectual Property Agency (CNIPA). The patent entitled “A METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS” covers the Company’s unique algorithm incorporated in the GA-map® technology for profiling gut microbiota. The positive decision from the Chinese patent authority means that the protection of the GA-map® technology has been substantially strengthened and will further support the Company’s expansion strategy into the Chinese market.
The subject matter of this family of patents relates to the sophisticated algorithms developed by Genetic Analysis that analyse and characterize gut microbiota in relation to healthy populations. The invention concerns the diagnosis, monitoring and/or characterization of diseases and conditions associated with perturbations in the microbiota of the gastrointestinal tract (GI). More specifically, the invention provides means by which the state of the microbiota may be assessed, and deviations (dysbiosis) from the normal state (normobiosis) may be determined in a manner that is straightforward to perform, reliable and robust.
The patent family claims priority from 27 March 2015 and will be in force until 2036.
CEO Ronny Hermansen comments:
”We are delighted to announce that our patent ‘A method for determining gastrointestinal tract dysbiosis’ has been allowed in China. The approval further strengthens our intellectual property portfolio which already includes the US and European patents and is an important milestone in GA´s plans to enter the growing Chinese market using funds from our recent successful IPO.”
The Company has an active patent strategy covering all major geographical markets, including Asia.
This information is such information that Genetic Analysis AS is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on 14 October 2021.
For further information, please contact:
Ronny Hermansen, Chief Executive Officer
E-mail: rh@genetic-analysis.com
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need of further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA holds 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com
Tags: